1. Home
  2. RAND vs ATNM Comparison

RAND vs ATNM Comparison

Compare RAND & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

N/A

Current Price

$12.15

Market Cap

32.4M

Sector

Finance

ML Signal

N/A

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

N/A

Current Price

$1.21

Market Cap

36.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RAND
ATNM
Founded
1969
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.4M
36.8M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
RAND
ATNM
Price
$12.15
$1.21
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
3.3K
115.6K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
9.87%
N/A
EPS Growth
N/A
30.60
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.05
$1.02
52 Week High
$26.00
$1.95

Technical Indicators

Market Signals
Indicator
RAND
ATNM
Relative Strength Index (RSI) 59.64 52.28
Support Level $10.56 $1.02
Resistance Level $12.50 $1.71
Average True Range (ATR) 0.41 0.07
MACD 0.13 0.02
Stochastic Oscillator 93.29 77.78

Price Performance

Historical Comparison
RAND
ATNM

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: